Amgen Operating Expenses Growth & History (AMGN)
Amgen's operating expenses was $27.67B for fiscal 2025.
View full Amgen company overviewAmgen annual operating expenses history
| Fiscal year | Period ended | Operating expenses | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $27.67B | $1.50B | +5.75% |
| 2024 | 2024-12-31 | $26.17B | $5.87B | +28.94% |
| 2023 | 2023-12-31 | $20.29B | $3.54B | +21.10% |
| 2022 | 2022-12-31 | $16.76B | −$1.58B | −8.63% |
| 2021 | 2021-12-31 | $18.34B | $2.06B | +12.62% |
| 2020 | 2020-12-31 | $16.29B | $2.60B | +18.97% |
| 2019 | 2019-12-31 | $13.69B | $204.0M | +1.51% |
| 2018 | 2018-12-31 | $13.48B | $608.0M | +4.72% |
| 2017 | 2017-12-31 | $12.88B | −$321.0M | −2.43% |
| 2016 | 2016-12-31 | $13.20B | $5.0M | +0.04% |
| 2015 | 2015-12-31 | $13.19B | −$680.0M | −4.90% |
| 2014 | 2014-12-31 | $13.87B | $1.06B | +8.30% |
| 2013 | 2013-12-31 | $12.81B | $1.12B | +9.59% |
| 2012 | 2012-12-31 | $11.69B | $418.0M | +3.71% |
| 2011 | 2011-12-31 | $11.27B | $1.76B | +18.53% |
| 2010 | 2010-12-31 | $9.51B | $372.0M | +4.07% |
| 2009 | 2009-12-31 | $9.14B | −$653.0M | −6.67% |
| 2008 | 2008-12-31 | $9.79B | −$1.00B | −9.29% |
| 2007 | 2007-12-31 | $10.79B | — | — |
Amgen quarterly operating expenses
| Fiscal quarter | Period ended | Operating expenses | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $6.54B | $17.0M | +0.26% |
| Q1 2026 | 2026-03-31 | $5.95B | −$1.02B | −14.62% |
| Q4 2025 | 2025-12-31 | $7.15B | $371.0M | +5.48% |
| Q3 2025 | 2025-09-30 | $7.03B | $575.0M | +8.91% |
| Q2 2025 | 2025-06-30 | $6.52B | $44.0M | +0.68% |
| Q1 2025 | 2025-03-31 | $6.97B | $515.0M | +7.98% |
| Q4 2024 | 2024-12-31 | $6.78B | −$150.0M | −2.17% |
| Q3 2024 | 2024-09-30 | $6.46B | $1.57B | +32.24% |
| Q2 2024 | 2024-06-30 | $6.48B | $2.18B | +50.60% |
| Q1 2024 | 2024-03-31 | $6.46B | $2.27B | +54.30% |
| Q4 2023 | 2023-12-31 | $6.92B | $2.32B | +50.25% |
| Q3 2023 | 2023-09-30 | $4.88B | $890.0M | +22.29% |
| Q2 2023 | 2023-06-30 | $4.30B | −$116.0M | −2.63% |
| Q1 2023 | 2023-03-31 | $4.18B | $446.0M | +11.93% |
| Q4 2022 | 2022-12-31 | $4.61B | $67.0M | +1.48% |
| Q3 2022 | 2022-09-30 | $3.99B | −$336.0M | −7.76% |
| Q2 2022 | 2022-06-30 | $4.42B | −$1.28B | −22.46% |
| Q1 2022 | 2022-03-31 | $3.74B | −$34.0M | −0.90% |
| Q4 2021 | 2021-12-31 | $4.54B | −$84.0M | −1.82% |
| Q3 2021 | 2021-09-30 | $4.33B | $358.0M | +9.02% |
| Q2 2021 | 2021-06-30 | $5.70B | $1.81B | +46.74% |
| Q1 2021 | 2021-03-31 | $3.77B | −$34.0M | −0.89% |
| Q4 2020 | 2020-12-31 | $4.63B | $477.0M | +11.50% |
| Q3 2020 | 2020-09-30 | $3.97B | $709.0M | +21.74% |
| Q2 2020 | 2020-06-30 | $3.88B | $690.0M | +21.61% |
| Q1 2020 | 2020-03-31 | $3.81B | $721.0M | +23.37% |
| Q4 2019 | 2019-12-31 | $4.15B | $301.0M | +7.82% |
| Q3 2019 | 2019-09-30 | $3.26B | −$320.0M | −8.94% |
| Q2 2019 | 2019-06-30 | $3.19B | −$34.0M | −1.05% |
| Q1 2019 | 2019-03-31 | $3.08B | $257.0M | +9.09% |
| Q4 2018 | 2018-12-31 | $3.85B | $291.0M | +8.18% |
| Q3 2018 | 2018-09-30 | $3.58B | $247.0M | +7.41% |
| Q2 2018 | 2018-06-30 | $3.23B | $115.0M | +3.70% |
| Q1 2018 | 2018-03-31 | $2.83B | −$45.0M | −1.57% |
| Q4 2017 | 2017-12-31 | $3.56B | $77.0M | +2.21% |
| Q3 2017 | 2017-09-30 | $3.33B | $50.0M | +1.52% |
| Q2 2017 | 2017-06-30 | $3.11B | −$196.0M | −5.93% |
| Q1 2017 | 2017-03-31 | $2.87B | −$252.0M | −8.06% |
| Q4 2016 | 2016-12-31 | $3.48B | −$23.0M | −0.66% |
| Q3 2016 | 2016-09-30 | $3.28B | −$100.0M | −2.96% |
| Q2 2016 | 2016-06-30 | $3.31B | $14.0M | +0.43% |
| Q1 2016 | 2016-03-31 | $3.13B | $114.0M | +3.79% |
| Q4 2015 | 2015-12-31 | $3.50B | −$369.0M | −9.53% |
| Q3 2015 | 2015-09-30 | $3.38B | −$181.0M | −5.08% |
| Q2 2015 | 2015-06-30 | $3.29B | $16.0M | +0.49% |
| Q1 2015 | 2015-03-31 | $3.01B | −$146.0M | −4.62% |
| Q4 2014 | 2014-12-31 | $3.87B | $48.0M | +1.26% |
| Q3 2014 | 2014-09-30 | $3.56B | $505.0M | +16.50% |
| Q2 2014 | 2014-06-30 | $3.28B | $149.0M | +4.76% |
| Q1 2014 | 2014-03-31 | $3.16B | $361.0M | +12.91% |
| Q4 2013 | 2013-12-31 | $3.82B | $491.0M | +14.73% |
| Q3 2013 | 2013-09-30 | $3.06B | $164.0M | +5.66% |
| Q2 2013 | 2013-06-30 | $3.13B | $241.0M | +8.34% |
| Q1 2013 | 2013-03-31 | $2.80B | $225.0M | +8.75% |
| Q4 2012 | 2012-12-31 | $3.33B | $522.0M | +18.57% |
| Q3 2012 | 2012-09-30 | $2.90B | −$523.0M | −15.30% |
| Q2 2012 | 2012-06-30 | $2.89B | $261.0M | +9.94% |
| Q1 2012 | 2012-03-31 | $2.57B | $158.0M | +6.55% |
| Q4 2011 | 2011-12-31 | $2.81B | $38.0M | +1.37% |
| Q3 2011 | 2011-09-30 | $3.42B | $1.08B | +46.30% |
| Q2 2011 | 2011-06-30 | $2.63B | $340.0M | +14.87% |
| Q1 2011 | 2011-03-31 | $2.41B | $302.0M | +14.31% |
| Q4 2010 | 2010-12-31 | $2.77B | $87.0M | +3.24% |
| Q3 2010 | 2010-09-30 | $2.34B | $130.0M | +5.89% |
| Q2 2010 | 2010-06-30 | $2.29B | $31.0M | +1.37% |
| Q1 2010 | 2010-03-31 | $2.11B | $124.0M | +6.24% |
| Q4 2009 | 2009-12-31 | $2.69B | — | — |
| Q3 2009 | 2009-09-30 | $2.21B | −$185.0M | −7.73% |
| Q2 2009 | 2009-06-30 | $2.26B | −$329.0M | −12.73% |
| Q1 2009 | 2009-03-31 | $1.99B | — | — |
| Q3 2008 | 2008-09-30 | $2.39B | — | — |
| Q2 2008 | 2008-06-30 | $2.58B | — | — |
Amgen operating expenses trends
Over the last five fiscal years, Amgen's operating expenses increased from $16.29B to $27.67B, a change of $11.39B. The latest reported quarter, Q2 2026, shows $6.54B.
What operating expenses mean
Operating expenses are the recurring costs of running a company’s business beyond the direct costs used to calculate gross profit. They commonly include selling, general and administrative expenses, research and development, and other operating costs.
SEC-reported and calculated operating expenses
TickerStat uses operating expenses reported in company SEC filings when available. When a separate total is unavailable, it calculates operating expenses as aligned gross profit minus operating income for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Amgen source filings ↗